Fig. 2From: Shaking up the silence: consequences of HMGN1 antagonizing PRC2 in the Down syndrome brainSchematic illustrating the effects of increased dosage of HMGN1 in DS through the antagonizing action on PRC2. The epigenetic changes induced by increased levels of PRC2 lead to diverse transcriptomic and phenotypic changes that can potentially lead to the pathological features observed in DS. Created with BioRender.comBack to article page